Microbot Medical Inc. (NASDAQ:MBOT) Stock Has Average Target Price of $6.38 According to Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have been given an average rating of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $6.38.

A number of brokerages recently weighed in on MBOT. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a report on Friday, October 2nd. Zacks Research downgraded Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research note on Wednesday, August 19th. Finally, B. Riley Financial initiated coverage on shares of Microbot Medical in a research note on Friday, September 11th. They set a “buy” rating and a $4.00 target price for the company.

Microbot Medical Price Performance

Microbot Medical stock opened at $0.95 on Friday. The firm has a 50-day moving average of $1.37 and a 200-day moving average of $1.76. Microbot Medical has a one year low of $0.93 and a one year high of $2.89. The company has a market cap of $63.81 million, a price-to-earnings ratio of -3.96 and a beta of 1.05.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. As a group, sell-side analysts expect that Microbot Medical will post -0.30 earnings per share for the current year.

Institutional Trading of Microbot Medical

Several institutional investors have recently added to or reduced their stakes in MBOT. CTC Alternative Strategies Ltd. bought a new position in Microbot Medical during the 1st quarter worth $28,000. Bank of America Corp DE grew its position in shares of Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 71,560 shares in the last quarter. Cetera Investment Advisers grew its position in Microbot Medical by 44.7% during the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after buying an additional 13,099 shares in the last quarter. Private Advisor Group LLC bought a new position in Microbot Medical during the 1st quarter worth $54,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Microbot Medical during the 4th quarter worth $65,000. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.

Microbot Medical’s primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures.